@article {1303717,
	title = {Injectable, Tough Alginate Cryogels as Cancer Vaccines},
	journal = {Adv Healthc Mater},
	year = {2018},
	month = {2018 Feb 14},
	abstract = {A covalently crosslinked methacrylated (MA)-alginate cryogel vaccine has been previously shown to generate a potent response against murine melanoma, but is not mechanically robust and requires a large 16G needle for delivery. Here, covalent and ionic crosslinking of cryogels are combined with the hypothesis that this will result in a tough MA-alginate cryogel with improved injectability. All tough cryogels can be injected through a smaller, 18G needle without sustaining any damage, while covalently crosslinked-only cryogels break after injection. Cytosine-phosphodiester-guanine (CpG)-delivering tough cryogels effectively activate dendritic cells (DCs). Granulocyte macrophage colony-stimulating factor releasing tough cryogels recruit four times more DCs than blank gels by day 7 in vivo. The tough cryogel vaccine induces strong antigen-specific cytotoxic T-lymphocyte and humoral responses. These vaccines prevent tumor formation in 80\% of mice inoculated with HER2/neu-overexpressing DD breast cancer cells. The MA-alginate tough cryogels provide a promising minimally invasive delivery platform for cancer vaccinations.},
	issn = {2192-2659},
	doi = {10.1002/adhm.201701469},
	author = {Shih, Ting-Yu and Blacklow, Serena O and Li, Aileen W and Freedman, Benjamin R and Bencherif, Sidi and Koshy, Sandeep T and Darnell, Max C and Mooney, David J}
}
